These results suggest that the observed differences in CRP are likely attributable to the underlying clinical characteristics of GLP-1 users, namely, higher rates of obesity, diabetes, and poorer glycemic control, rather than a direct anti-inflammatory effect of the medication. This evidence concerns the gene CRP and obesity due to melanocortin 4 receptor deficiency.